Orgalutran

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

ganirelix

Available from:

N.V. Organon

ATC code:

H01CC01

INN (International Name):

ganirelix

Therapeutic group:

Ormoni u analogi pitwitarji u ipotalamiċi

Therapeutic area:

Reproductive Techniques, Assisted; Ovulation Induction; Infertility, Female

Therapeutic indications:

Il-prevenzjoni ta 'żidiet prematuri ta' l-ormon ta 'luteinizzazzjoni f'nisa li għaddejjin minn stimulazzjoni eċċessiva kkontrollata ta' l-ovarji għal tekniki ta 'riproduzzjoni assistita. Fi studji kliniċi, Orgalutran ntuża ma uman rikombinanti-follikulu l-ormoni li jistimulaw jew corifollitropin alfa, il-sostnut follikulu stimulant.

Product summary:

Revision: 24

Authorization status:

Awtorizzat

Authorization date:

2000-05-16

Patient Information leaflet

                                17
B. FULJETT TA’ TAGĦRIF
18
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
ORGALUTRAN 0.25 MG/0.5 ML SOLUZZJONI GĦALL-INJEZZJONI
ganirelix
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TUŻA DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispiżjar jew
l-infermier tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M'għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib, lill-ispiżjar jew
l-infermier tiegħek. Dan
jinkludi xi effett sekondarju possibbli li mhuwiex elenkat f’dan
il-fuljett.
Ara sezzjoni 4.
F'DAN IL-FULJETT:
1.
X’inhu Orgalutran u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tuża Orgalutran
3.
Kif għandek tuża Orgalutran
4.
Effetti sekondarji possibbli
5.
Kif taħżen Orgalutran
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU ORGALUTRAN U GЋALXIEX JINTUŻA
Orgalutran fih is-sustanza attiva ganirelix u jappartjeni għal grupp
ta' mediċini msejħa "ormoni li jerħu
anti-gonadotropin" li jaġixxu kontra l-azzjonijiet tal-ormon naturali
li jeħles il-gonadotrophin (GnRH).
GnRH jirregola ir-rilaxx ta' gonadotrophins (ormon luteinizzanti (LH)
u ormon li jistimula l-follikuli
(FSH)). Il-gonadotrophins għandhom rwol importanti fil-fertilità u
r-riproduzzjoni umana. Fin-nisa, l-
FSH hu meħtieġ għat-tkabbir u l-iżvilupp tal-follikoli fl-ovarji.
Il-follikoli huma boroż zgħar u tondi li
fihom iċ-ċelluli tal-bajd. LH hu meħtieġ biex joħroġ
iċ-ċelluli maturi tal-bajda mill-follikoli u l-ovarji
(i.e. ovalazzjoni). Orgalutran jimpedixxi l-azzjoni ta' GnRH, li
jirriżulta fit-trażżin tar-rilaxx, l-aktar ta'
LH.
Orgalutran jintuża għal
Fil-każ ta' nisa li jingħataw tekniċi tar-riproduzzjoni assistita,
inkluż fertilizzazzjoni in vitro (IVF) u
metodi oħra, kultant jiġri li l-ovulazzj
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Orgalutran 0.25 mg/0.5 mL soluzzjoni għal injezzjoni
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull siringa mimlija lesta ta' Orgalutran fiha s-sustanza attiva
ganirelix, 0.25 mg f’soluzzjoni ta'
0.5 mL ta' ilma. Is-sustanza attiva ganirelix (INN) hi decapeptide
sintetiku, li għandu attività għolja
antagonistika għal ormon li jinstab b'mod naturali, ormon li jeħles
il-gonadotrophin (GnRH). L-amino
acids li jinsabu fil-pożizzjonijiet 1, 2, 3, 6, 8 u 10
tad-decapeptide naturali GnRH ġew issostitwiti u
rriżultaw f' N-Ac-D-Nal(2)
1
, D-pClPhe
2
, D-Pal(3)
3
, D-hArg(Et2)
6
, L-hArg(Et2)
8
, D-Ala
10
]-GnRH. Il-piż
molekulari huwa ta' 1570.4.
Eċċipjent b’effett magħruf
Dan il-prodott mediċinali fih anqas minn 1 mmol sodium (23 mg)
f’kull injezzjoni, jiġifieri
essenzjalment ‘ħieles mis-sodium’.
Għal-lista kompluta ta' eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Soluzzjoni għal injezzjoni.
Soluzzjoni ta' l-ilma li hi ċara u bla kulur.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Orgalutran huwa indikat għall-prevenzzjoni ta' żjieda primatura
fil-livelli ta' l-ormon lutejnizzanti (LH)
fin-nisa, li jingħataw terapija ta' stimulazzjoni eċċessiva
kkontrollata ta' l-ovarji (COH) għat-teknika ta'
riproduzzjoni assistita (ART).
Fi studji kliniċi, Orgalutran ntuża ma' l-ormon rikombinanti li
jistimula l-follikulu uman (FSH) jew
corifollitropin alfa, l-istimulant sostnut tal-follikuli.
4.2
POŻOLOĠIJA U METODU TA' KIF GĦANDU JINGĦATA
Orgalutran għandu jiġi ordnat biss minn speċjalisti li għandhom
esperjenza fit-trattament ta' l-infertilità.
Pożoloġija
Orgalutran jingħata biex jiprevjeni żjidiet primaturi fil-livell ta'
l-LH, f nisa li jkunu għaddejjin bit-
trattament ta' l-(COH). L-istimulazzjoni eċċessiva kkontrollata ta'
l-ovarji permezz tal-FSH jew
corifollitropin alfa, tista' tibda fit-2 jew 3 jum tal-mestrwu.
Orgalutran (0.25 mg) għandu jingħata
b'injezzjoni waħda ku
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-04-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-04-2023
Public Assessment Report Public Assessment Report Bulgarian 21-07-2013
Patient Information leaflet Patient Information leaflet Spanish 04-04-2023
Public Assessment Report Public Assessment Report Spanish 21-07-2013
Patient Information leaflet Patient Information leaflet Czech 04-04-2023
Public Assessment Report Public Assessment Report Czech 21-07-2013
Patient Information leaflet Patient Information leaflet Danish 04-04-2023
Public Assessment Report Public Assessment Report Danish 21-07-2013
Patient Information leaflet Patient Information leaflet German 04-04-2023
Public Assessment Report Public Assessment Report German 21-07-2013
Patient Information leaflet Patient Information leaflet Estonian 04-04-2023
Public Assessment Report Public Assessment Report Estonian 21-07-2013
Patient Information leaflet Patient Information leaflet Greek 04-04-2023
Public Assessment Report Public Assessment Report Greek 21-07-2013
Patient Information leaflet Patient Information leaflet English 04-04-2023
Public Assessment Report Public Assessment Report English 21-07-2013
Patient Information leaflet Patient Information leaflet French 04-04-2023
Public Assessment Report Public Assessment Report French 21-07-2013
Patient Information leaflet Patient Information leaflet Italian 04-04-2023
Public Assessment Report Public Assessment Report Italian 21-07-2013
Patient Information leaflet Patient Information leaflet Latvian 04-04-2023
Public Assessment Report Public Assessment Report Latvian 21-07-2013
Patient Information leaflet Patient Information leaflet Lithuanian 04-04-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-04-2023
Public Assessment Report Public Assessment Report Lithuanian 21-07-2013
Patient Information leaflet Patient Information leaflet Hungarian 04-04-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 04-04-2023
Public Assessment Report Public Assessment Report Hungarian 21-07-2013
Patient Information leaflet Patient Information leaflet Dutch 04-04-2023
Public Assessment Report Public Assessment Report Dutch 21-07-2013
Patient Information leaflet Patient Information leaflet Polish 04-04-2023
Public Assessment Report Public Assessment Report Polish 21-07-2013
Patient Information leaflet Patient Information leaflet Portuguese 04-04-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 04-04-2023
Public Assessment Report Public Assessment Report Portuguese 21-07-2013
Patient Information leaflet Patient Information leaflet Romanian 04-04-2023
Public Assessment Report Public Assessment Report Romanian 21-07-2013
Patient Information leaflet Patient Information leaflet Slovak 04-04-2023
Public Assessment Report Public Assessment Report Slovak 21-07-2013
Patient Information leaflet Patient Information leaflet Slovenian 04-04-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 04-04-2023
Public Assessment Report Public Assessment Report Slovenian 21-07-2013
Patient Information leaflet Patient Information leaflet Finnish 04-04-2023
Public Assessment Report Public Assessment Report Finnish 21-07-2013
Patient Information leaflet Patient Information leaflet Swedish 04-04-2023
Public Assessment Report Public Assessment Report Swedish 21-07-2013
Patient Information leaflet Patient Information leaflet Norwegian 04-04-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 04-04-2023
Patient Information leaflet Patient Information leaflet Icelandic 04-04-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 04-04-2023
Patient Information leaflet Patient Information leaflet Croatian 04-04-2023

Search alerts related to this product

View documents history